Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217249 | 1.00 | PPARG (0.76) | PPARGPPARA | |
| SCHEMBL28214088 | 0.93 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL9751930 | 0.92 | PPARG (0.79) | PPARGPPARA | |
| SCHEMBL4156967 | 0.88 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1719719 | 0.88 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL1749468 | 0.88 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL27413268 | 0.87 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL8335329 | 0.86 | PPARG (0.72) | PPARGPPARA | |
| SCHEMBL11878375 | 0.86 | PPARG (0.61) | PPARG | |
| SCHEMBL2785014 | 0.86 | PPARG (0.88) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | claimed |
| US-7368286-B2 | Method and device for identifying substances capable of modulating adipocyte differentiation | GENFIT (FR) | 2008-05-06 | — | — | US | claimed |
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | BALKAN BORK | 2008-03-27 | — | — | US | claimed |
| EP-1390026-A4 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050032064-A1 | Method and device for identifying substances capable of modulating adipocyte differentiation | GENFIT (FR) | 2005-02-10 | — | — | US | claimed |
| EP-1468078-A1 | METHOD AND DEVICE FOR IDENTIFYING SUBSTANCES CAPABLE OF MODULATING ADIPOCYTE DIFFERENTIATION | Genfit (FR) | 2004-10-20 | — | — | EP | claimed |
| US-20040171692-A1 | Modulation of bone formation | ANDREW SCUTT (GB) | 2004-09-02 | — | — | US | claimed |
| EP-1390026-A1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-02-25 | — | — | EP | claimed |
| JP-2003522787-A | — | — | 2003-07-29 | — | — | JP | claimed |
| US-20030139372-A1 | Modulation of bone formation | UNIVERSITY OF SHEFFIELD (GB) | 2003-07-24 | — | — | US | claimed |
| WO-2003060106-A1 | METHOD AND DEVICE FOR IDENTIFYING SUBSTANCES CAPABLE OF MODULATING ADIPOCYTE DIFFERENTIATION | GENFIT (FR) | 2003-07-24 | — | — | WO | claimed |
| EP-1259233-A1 | MODULATION OF BONE FORMATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-11-27 | — | — | EP | claimed |
| WO-2002089790-A1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| US-20020164385-A1 | Treatment of HPV caused diseases | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-07 | — | — | US | claimed |
| US-20020019344-A1 | Methods of preventing allograft rejection | PERSHADSINGH HARRIHAR A (US) | 2002-02-14 | — | — | US | claimed |
| US-6316465-B1 | Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists | PHOTOGENESIS, INC. | 2001-11-13 | — | — | US | claimed |
| WO-2001060355-A1 | MODULATION OF BONE FORMATION | UNIVERSITY OF SHEFFIELD (GB) | 2001-08-23 | — | — | WO | claimed |
| WO-2000000194-A1 | OPHTHALMIC USES OF PPARGAMMA AGONISTS AND PPARGAMMA ANTAGONISTS | PHOTOGENESIS, INC. (US) | 2000-01-06 | — | — | WO | claimed |
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076811-A1 | COMBINATIONS COMPRISING DEPEPTIDYPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | G6PC1, GCK, PDK4 | PPARG 78/4885PPARA 554/4885 |
| US-20020164385-A1 | Treatment of HPV caused diseases | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885 |
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | DPP4, DPP7, DPP3 | PPARG 695/4885PPARA 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.